Modak, Shakeel <br/><br/>
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.  [electronic resource] 

 -  Journal of nuclear medicine : official publication, Society of Nuclear Medicine  Feb 2016 
 - 231-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1535-5667 
<br/><br/><label>Standard No.: </label>10.2967/jnumed.115.161752  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Iodobenzylguanidine--adverse effects<br/>Adolescent<br/>Adrenal Gland Neoplasms--radiotherapy<br/>Adult<br/>Arsenic Trioxide<br/>Arsenicals--adverse effects<br/>Brain Neoplasms--radiotherapy<br/>Child<br/>Child, Preschool<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Male<br/>Neuroblastoma--radiotherapy<br/>Oxides--adverse effects<br/>Paraganglioma--radiotherapy<br/>Pheochromocytoma--radiotherapy<br/>Radiation-Sensitizing Agents--adverse effects<br/>Radiopharmaceuticals--adverse effects<br/>Survival Analysis<br/>Treatment Outcome